In a report released today, Matthew Cross from Alliance Global Partners maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $20.00. The company's shares closed last Tuesday at $6.38, close to its 52-week low of $5.70. According to TipRanks.com, Cross is a 3-star analyst with an average return of 6.8% and a 35.4% success rate. Cross covers the Healthcare sector, focusing on stocks such as Syros Pharmaceuticals, Aptose Biosciences, and Gamida Cell. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $28.15 average price target, representing a 309.2% upside.
https://www.tipranks.com/news/blurbs/alliance-global-partners-thinks-actinium-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Actinium Pharmaceuticals Charts.
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Actinium Pharmaceuticals Charts.